Trial Profile
Safety and efficacy of apatinib plus S-1 after failure of second-line or third-line chemotherapy in patients with advanced non-small cell lung cancer: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
- 01 Jun 2017 Recruitment completed, according to results presented at the 18th World Conference on Lung Cancer.